TDC
AEGR

Thompson Davis & Co’s Aegerion Pharmaceuticals AEGR Stock Holding History

Thompson Davis & Co’s Portfolio AEGR Stock Details AEGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-125
Closed -$4K – 1341
2014
Q3 		$4K Buy
+125
New +$3.88K 0.01% 970

Other funds holding AEGR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Thompson Davis & Co's AEGR Position: Q4 2014 in Review

Thompson Davis & Co sold out of Aegerion Pharmaceuticals (AEGR) in Q4 2014, closing a stake of 125 shares — an estimated $4K sold.

Thompson Davis & Co first reported a position in AEGR in Q3 2014 and held it in 1 quarter. The position peaked at $4K in Q3 2014. 95 funds tracked by Wall St. Rank hold AEGR as of Q4 2014.

  • Thompson Davis & Co reported no remaining Aegerion Pharmaceuticals position as of Q4 2014 after selling out during the quarter.
  • Thompson Davis & Co sold 125 Aegerion Pharmaceuticals shares in Q4 2014, an estimated $4K.
  • Thompson Davis & Co first reported a position in Aegerion Pharmaceuticals in Q3 2014 and held it in 1 quarter.
  • Thompson Davis & Co's Aegerion Pharmaceuticals position peaked at $4K in Q3 2014.
  • 95 funds tracked by Wall St. Rank held Aegerion Pharmaceuticals as of Q4 2014.

Based on Thompson Davis & Co's 13F filing for Q4 2014, filed 6 Feb 2015.